BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.15 USD
+0.11 (1.56%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $7.16 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCRX 7.15 +0.11(1.56%)
Will BCRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Other News for BCRX
ORLADEYO® (berotralstat) Approved in Peru
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Recursion Pharmaceuticals (RXRX) and Progyny (PGNY)
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Analysts Offer Insights on Healthcare Companies: Standard BioTools (LAB), BioCryst (BCRX) and Alnylam Pharma (ALNY)